Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Wei Wang, Qi Li, Tadaaki Yamada, Kunio Matsumoto, Isao Matsumoto, Makoto Oda, Go Watanabe, Yoshiyuki Kayano, Yasuhioko Nishioka, Saburo Sone, and Seiji Yano

Abstract

Purpose: Lung cancers with epidermal growth factor receptor (EGFR)-activating mutations show good clinical response to gefitinib and erlotinib, selective tyrosine kinase inhibitors (TKI) to EGFR, but these tumors invariably develop drug resistance. Host stromal cells have been found to have a considerable effect on the behavior of cancer cells. Little is known, however, about the role of host cells on the sensitivity of cancer cells to receptor TKIs. We have therefore assessed the effect of crosstalk between stromal cells and lung cancer cells harboring EGFR mutations on susceptibility to EGFR-TKIs.

Experimental Design: We evaluated the gefitinib sensitivity of lung cancer cells with EGFR-activating mutations, PC-9 and HCC827, when cocultured with fibroblasts and co-injected into severe combined immunodeficient mice. We also examined the effect of lung cancer cells to fibroblast recruitment.

Results: Both human fibroblast cell lines and primary cultured fibroblasts produced various levels of hepatocyte growth factor (HGF). Lung cancer cells markedly recruited fibroblasts. The lung cancer cells became resistant to EGFR-TKIs when cocultured in vitro with HGF-producing fibroblasts and co-injected into severe combined immunodeficient mice. Importantly, combined use of gefitinib plus anti-HGF antibody or the HGF antagonist, NK4, successfully overcame the fibroblast-induced EGFR-TKI resistance both in vitro and in vivo. Colocalization of fibroblasts and HGF was detected in both xenograft tumors in mouse model and lung cancer patient specimens.

Conclusions: These findings indicate that crosstalk to stromal fibroblasts plays a critical role in lung cancer resistance to EGFR-TKIs and may be an ideal therapeutic target in lung cancer with EGFR-activating mutations. (Clin Cancer Res 2009;15(21):OF1–9)
EGFR-TKIs. In addition, almost all NSCLC patients with EGFR mutations who show response to gefitinib or erlotinib ultimately develop resistance to these agents (5). Therefore, it is essential to understand the mechanisms of resistance to gefitinib.

Studies over the last few years have identified two different EGFR-TKI resistance mechanisms, a secondary mutation in EGFR, EGFR T790M, and amplification of the MET oncogene, which have been reported in ~50% and 20%, respectively, of patients acquiring resistance to EGFR-TKIs (7–10). More recently, we identified a third mechanism of gefitinib resistance induced by hepatocyte growth factor (HGF; ref. 11). HGF was expressed in various types of cancer cells, including lung cancer.

The binding of HGF to MET induces pleiotropic biological effects in many cell types, including mitogenic, motogenic, morphogenic, and antiapoptotic activities (13, 14). We reported previously that HGF activated MET and directly restored the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, which have been reported in ~50% and 20%, respectively, of patients acquiring resistance to EGFR-TKIs (7–10). More recently, we identified a third mechanism of gefitinib resistance induced by hepatocyte growth factor (HGF; ref. 11). HGF was originally identified as a mitogenic protein for hepatocytes (12). Its specific receptor is MET, a tyrosine kinase overexpressed in various types of cancer cells, including lung cancer. The binding of HGF to MET induces pleiotropic biological effects in many cell types, including mitogenic, motogenic, morphogenic, and antiapoptotic activities (13, 14). We reported previously that HGF activated MET and directly restored the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, independent of EGFR or ErbB3, thus inducing gefitinib resistance of lung cancer cells with EGFR-activating mutations. Activated MET can be further upregulated by EGFR-TKI treatment; (b) coculture or coinjection of EGFR mutant lung cancer cells with human fibroblasts induced resistance to EGFR-TKIs by activating the MET/phosphoinositide 3-kinase/Akt axis in vitro and in vivo; (c) anti–hepatocyte growth factor (HGF) antibody, a HGF antagonist, NK4, and MET-TKI overcame the resistance to EGFR-TKIs of lung cancer; and (d) HGF high-producing fibroblasts were detected in both xenograft tumors in mouse model and lung cancer patient specimens. Our findings indicate that crosstalk to stromal fibroblasts plays a critical role in lung cancer resistance to EGFR-TKIs and may be an ideal therapeutic target in lung cancer with EGFR-activating mutations.

EGFR-TKIs of lung cancer cells with EGFR-activating mutations could be affected by crosstalk to the host microenvironment, focusing on host-cell derived HGF. We found that fibroblasts could be recruited by cancer cells and that fibroblast-derived HGF efficiently induced gefitinib resistance of lung cancer cells with EGFR-activating mutations. We also found that HGF-MET inhibitors, such as anti-HGF antibody and NK4, could circumvent HGF-induced gefitinib resistance.

**Materials and Methods**

**Cell culture and reagents.** The EGFR mutant human lung adenocarcinoma cell lines PC-9 (del E746_A750) and HCC827 (del E746_A750) were purchased from Immuno-Biological Laboratories and the American Type Culture Collection, respectively. These cell lines have been extensively characterized (9, 18, 19). Human embryonic fibroblasts MRC-5 and IMR-90 were obtained from RIKEN Cell Bank. Human endothelial cell lines, human dermal microvascular endothelial cells (HMVEC), and human umbilical vein endothelial cells (HUVEC) were purchased from Kurabo. The PC-9 and HCC827 cell lines were maintained in RPMI 1640 supplemented with 10% fetal bovine serum and antibiotics. The MRC-5 (P 30–35) and IMR-90 cell lines were cultured in 10% fetal bovine serum–DMEM. HUVEC and HMVEC cell lines (P 2–5) were maintained in HuMedia-MvG medium with growth supplements (Kurabo).

Gefitinib was obtained from AstraZeneca. Human recombinant HGF and human recombinant NK4 were prepared as described previously (20, 21). The purity of NK4 and HGF was >96% and >98%, respectively, as determined by SDS-PAGE and protein staining.

**Isolation of fibroblasts from patients lung cancer tissues.** Five patients with histologically proven lung cancer who underwent surgical resection in Kanazawa University Hospital were enrolled. The patient cancer cells were cultured from tissues. Cancer cell lines were maintained in RPMI 1640 supplemented with 10% fetal bovine serum and antibiotics. After 48 h, unattached cells were removed and fresh medium was added. After 7 to 10 days, the cells formed homogeneous monolayers morphologically consistent with fibroblast-like cells and were confirmed to consist of >99% type I collagen–positive cells (Supplementary Fig. S1). The study was carried out in accordance with the medical ethical committee guidelines of Kanazawa University.

**Cell proliferation assay.** Cell proliferation was measured using the MTT dye reduction method (23). Briefly, tumor cells (2 × 10^4 cells) were plated into each well of 96-well plates with or without gefitinib, cytotaxones, and/or culture supernatants for 72 h with additional 2 h incubation with MTT solution. The dark blue crystals were dissolved by adding 100 μL DMSO. The absorbance was measured with a microplate reader at test and reference wavelengths of 550 and 630 nm, respectively. Percent growth was determined relative to untreated controls. Each experiment was done at least three times, each with triplicate samples.

**Cell migration assay.** Cell migration assays were done using the modified Boyden chamber method (24), with an 8 μm pore filter separating the top and bottom Transwell chambers (BD Biosciences). The cells were serum starved for 24 h before the assay. MRC-5 or primary cultured fibroblasts (1 × 10^4 cells/200 μL RPMI 1640) were added to the top chamber, and PC-9 or HCC827 cells (5 × 10^4 cells/500 μL RPMI 1640, with or without 1 μmol/L gefitinib) were added to the bottom chambers. After 48 h incubation at 37°C, the cells that had not migrated were removed from the top surface of the filters with cotton swabs. The cells that had migrated to the bottom surface of the filters were fixed in methanol and stained with H&E. Invasion was quantitated by counting cells in six randomly selected fields on each filter.
a microscope at a ×200 magnification and graphed as the mean of three independent experiments.

**Coculture of lung cancer cells with fibroblasts.** Cells were cocultured in Transwell chambers separated by 8 μm pore filters. Tumor cells (8 × 10⁶ cells/700 μL) with or without gefitinib (0.3 μmol/L) were placed in the bottom chamber, and fibroblasts (10⁵ cells/300 μL), with or without 1 h pretreatment with control IgG or anti-HGF neutralizing antibody (2 μg/mL; R&D Systems), were placed in the top chamber. After 72 h, the top chamber was removed, and cell proliferation was measured with a Cell Counting Kit-8 (Dojindo). Each experiment was done at least three times, each with triplicate samples.

**Antibodies and Western blotting.** A Western blot analysis was done as described previously (11). The experiment was done in triplicate. The following antibodies were used: anti-Met (25H2), anti–phospho-Met (Y1234/Y1235; 3D7), anti–phospho-EGFR (Y1068), anti-ErbB3 (1B2), anti–phospho-ErbB3 (Tyr1289; 21D3), anti-Akt, or phospho-Akt (Ser473; Cell Signaling Technology) and anti-human EGFR, anti-human/mouse/rat extracellular signal-regulated kinase 1/2, and anti–phospho-extracellular signal-regulated kinase 1/2 (T202/Y204; R&D Systems).

**HGF production in cell culture supernatants and tumor tissues.** Cells (5 × 10⁶) were incubated for 48 h in 5 mL culture medium. Then, the supernatant was centrifuged and stored at -70°C. Tumors from severe combined immunodeficient (SCID) mice were lysed in mammalian tissue lysis buffer containing a phosphatase and proteinase inhibitor cocktail (Sigma). HGF was quantitated by ELISA in accordance with the manufacturer’s procedure (Immunis HGF EIA; Institute of Immunology). The detection limit was 0.1 ng/mL. All samples were run in triplicate.

**Xenograft studies in SCID mice.**Suspensions of PC-9 cells (5 × 10⁶) with or without MRC-5 (5 × 10⁶) were injected subcutaneously into the backs of 5-week-old female SCID mice (Clea). After 4 days (diameter > 4 mm), mice were randomized into groups of five animals to receive gefitinib (25 mg/kg/d) or vehicle only by oral gavage. In some groups, anti-HGF neutralizing antibody (5 mg/kg/d) or NK4 (9 mg/kg/d) was injected intraperitoneally. The tumor area was calculated (width × length). All animal experiments complied with the Guidelines for the Institute for Experimental Animals, Kanazawa University Advanced Science Research Center (approval no. AP-081088).

**Cell membrane fluorescence labeling.** MRC-5 cells were labeled with red fluorescence using PKH26 red fluorescent cell linker mini kit (Sigma) as described previously (25). Briefly, 2 μmol/L freshly prepared dye was added to 2 × 10⁷ cells/mL diluent C, and the samples were incubated at room temperature for 5 min with gentle mixing. Staining was

---

**Fig. 1.** Fibroblast-derived HGF induces gefitinib resistance in lung cancer cells. **A,** coculture with fibroblasts induces gefitinib resistance in lung cancer cells. The PC-9 and HCC827 lung cancer cell lines were cocultured with MRC-5 cells or HGF (20 ng/mL), with control IgG or anti-HGF neutralizing antibody (1 μg/mL), in the presence or absence of gefitinib (0.3 μmol/L) for 72 h, and lung cancer cell growth was determined with a Cell Counting Kit-8. *, P < 0.01 (one-way ANOVA). **B,** HGF production by lung cancer (PC-9 and HCC827), fibroblasts (MRC-5 and IMR-90), and endothelial (HMVEC and HUVEC) cell lines and by primary cultured fibroblasts from tumors of 5 lung cancer patients. Cells were incubated in medium for 48 h, culture supernatants were harvested, and HGF concentrations were determined by ELISA. **C,** colocalization of fibroblasts and HGF in tumor tissue from a lung cancer patient. Frozen tumor specimens were subjected to triple-color immunofluorescence analyses using the combination of anti–type I collagen antibody (green), anti-HGF antibody (red), and 4,6-diamidino-2-phenylindole (blue) as described in Materials and Methods. The fluorescent images were digitally merged. Representative result from lung cancer patient 2. Original magnification, ×200.
terminated by addition of four volumes of HBSS containing 10% fetal bovine serum. The labeled MRC-5 cells were coinjected with PC-9 cells subcutaneously into SCID mice.

**Immunofluorescence analysis.** Frozen tissue sections (4 μm thick) were fixed with cold acetone and washed with PBS. After blocking with 5% normal horse serum, the slides were incubated overnight at 4°C with goat anti-human type I collagen antibody (1:200; Southern Biotech) and 3 μg/mL rabbit anti-human HGFα (H163; ref. 26; IBL). After washing with PBS, the slides were stained with matched secondary antibodies conjugated with Alexa Fluor 594 (red) or Alexa Fluor 488 (green; 1:200 dilution; Invitrogen). The localized green and red fluorescence were detected by fluorescence microscope.

**Statistical analysis.** Differences were compared by one-way ANOVA. All statistical analyses were done using GraphPad Prism version 4.01 (GraphPad Software). P < 0.05 was considered significant.

Results

**Coculture with fibroblasts induces gefitinib resistance in lung cancer cells.** To investigate whether the gefitinib susceptibility of lung cancer cells with EGFR-activating mutations could be affected by crosstalk to the host microenvironment, we cocultured PC-9 and HCC827 cells with fibroblast cell lines using Transwell systems. Whereas PC-9 and HCC827 cells were highly sensitive to gefitinib, exogenously added HGF induced gefitinib resistance in these cells as reported previously (11). Coculture with MRC-5 cells slightly stimulated the proliferation of PC-9 and HCC827 cells. Under these experimental conditions, both PC-9 and HCC827 cells became highly resistant to gefitinib in the presence of MRC-5 cells, but this resistance was canceled by treatment with anti-HGF neutralizing antibody (Fig. 1A). Similar results were obtained using a second fibroblast cell line, IMR-90, but not endothelial cell lines, HUVEC or HMVEC (data not shown). These results suggested that fibroblast-derived HGF induced gefitinib resistance in lung cancer cells with EGFR-activating mutations.

**HGF production by lung cancer cells and cancer stromal cells.** Then, we examined the production of HGF by various cell lines, including human lung cancer cells, fibroblasts, and endothelial cells. We found that the lung cancer cell lines, PC-9 and HCC827, did not secrete detectable levels of HGF into their culture supernatants nor did HUVEC and HMVEC cells (Fig. 1B). In contrast, the human fibroblast cell lines, MRC-5 and IMR-90, produced high levels of HGF. Because only fibroblast cell lines produced high levels of HGF, we sought to examine HGF production by cancer-associated fibroblasts. We successfully established primary cultures of fibroblasts in tumors from 5 lung cancer patients and found that these cells produced various levels of HGF, with the highest observed in fibroblasts from patient 2 (PF2), 83 ng HGF per million cells. Immunohistochemical staining for HGF revealed that tumor fibroblasts from patient 2 also produced HGF in vivo (Fig. 1C).

**Lung cancer cells induce recruitment of fibroblasts.** Cancer-associated fibroblasts have been shown to possess heterogeneous origins and characteristics (26). These cells originate from local resident fibroblasts and from bone marrow–derived stromal cells. We speculated that lung cancer cells might affect
the behavior of fibroblasts, particularly their recruitment. We therefore assessed the effect of lung cancer cells on fibroblast migration. In the presence of medium alone, few MRC-5 cells migrated through the filters; in contrast, PC-9 (Fig. 2) and HCC827 (data not shown) cells dramatically induced MRC-5 cell migration. PC-9 cells also induced migration of the primary cultured fibroblasts, which was not abrogated by imatinib (inhibitor of platelet-derived growth factor receptors) or antibodies against fibronectin, fibroblast growth factor-2, platelet-derived growth factor-AA, platelet-derived growth factor-BB, stromal cell-derived factor-1, heparin-binding epidermal growth factor, or interleukin-8 (data not shown). These data suggest that lung tumors may recruit fibroblasts to make these tumors resistant to gefitinib.

Fibroblast supernatants induce gefitinib resistance in lung cancer cells. To further confirm the effect of HGF derived from fibroblasts, we examined the effect of supernatants of fibroblasts and endothelial cells on the gefitinib sensitivity of PC-9 and HCC827 cells. The culture supernatants of MRC-5 and IMR-90 cells made PC-9 and HCC827 cells highly resistant to gefitinib. Pretreatment of these supernatants with anti-HGF neutralizing antibody, but not control IgG, entirely abrogated the resistance induced by the supernatants of MRC-5 and IMR-90 cells (Fig. 3A). In contrast, the supernatants of HMVEC or HUVEC did not affect the gefitinib sensitivity of PC-9 or HCC827 cells (data not shown). Moreover, supernatants of primary cultured fibroblasts obtained from lung cancer patients induced gefitinib resistance in PC-9 cells (Fig. 3B), with the level of resistance correlating with HGF production by fibroblasts. The supernatants of PF2 made PC-9 cells completely resistant to gefitinib, whereas the supernatants of primary cultured fibroblasts obtained from other patients induced only partial resistance to gefitinib. Importantly, anti-HGF antibody significantly restored the sensitivity of PC-9 cells to gefitinib in all 5 patients.

In parallel experiments, HGF induced resistance of PC-9 cells to erlotinib (Fig. 3C).

HGF derived from fibroblasts restores PI3K/Akt pathway via MET but not EGFR or ErbB3. We reported previously that, in the presence of gefitinib, HGF phosphorylated MET and restored the signal for Akt and extracellular signal-regulated kinase 1/2 independent of EGFR or ErbB3 in lung cancer cells harboring EGFR-activating mutations (11). We found that culture supernatants of PF2 cells containing 80 ng/mL HGF did not affect the phosphorylation of EGFR or ErbB3 (Fig. 4). In contrast, these HGF-containing supernatants stimulated the phosphorylation of MET and restored the phosphorylation of Akt and extracellular signal-regulated kinase 1/2 that had been inhibited by gefitinib. These effects were abrogated by pretreatment of the culture supernatants with anti-HGF neutralizing antibody, indicating that HGF produced by PF2 cells restored the phosphorylation of PI3K/Akt via MET, but not via EGFR.

**Fig. 3.** Fibroblast supernatants induce gefitinib resistance in lung cancer cells. A, supernatants of human fibroblast cell lines, MRC-5 and IMR-90, induce gefitinib resistance in PC-9 and HCC827 cells. Lung cancer cells were incubated for 72 h with or without gefitinib (0.3 μmol/L) in the presence of culture supernatants of MRC-5 or IMR-90 cells (ratio of 1:2) with or without 1 h pretreatment with control IgG or anti-HGF neutralizing antibody (1 μg/mL). Lung cancer cell growth was determined by MTT assays. *, P < 0.01 (one-way ANOVA). B, supernatants of primary cultured fibroblasts from lung cancer patients (PF) induce gefitinib resistance in lung cancer cells. Lung cancer cells were incubated for 72 h with or without gefitinib (0.3 μmol/L) in the presence of culture supernatants of PF1 or PF2 (ratio of 1:2) with or without 1 h pretreatment with control IgG or anti-HGF neutralizing antibody (1 μg/mL). Lung cancer cell growth was determined by MTT assays. *, P < 0.01 (one-way ANOVA). C, HGF induces lung cancer cell resistance to erlotinib. PC-9 cells were incubated for 72 h with various concentrations of erlotinib and/or HGF (20 ng/mL), and cell growth was determined by MTT assays.
or ErbB3, in lung cancer cells harboring EGFR-activating mutations. These results confirm the importance of fibroblast-derived HGF in the gefitinib resistance of lung cancer cells with EGFR-activating mutations and further indicate that HGF may be a therapeutic target for overcoming resistance to gefitinib.

Several inhibitors of HGF-MET have been developed recently, including anti-HGF antibody, natural antagonist NK4, and MET-TKI. We therefore tested whether these inhibitors could overcome gefitinib resistance induced by fibroblast-derived HGF. We found that 3 μmol/L (nontoxic concentration) of the MET-TKI, SU11274, moderately reversed the HGF-induced gefitinib resistance of PC-9 cells. In contrast, both anti-HGF neutralizing antibody (1 μg/mL) and the natural HGF inhibitor NK4 (300 nmol/L) completely overcame the gefitinib resistance at nontoxic concentrations (Fig. 5).

HGF derived from fibroblasts induces gefitinib resistance of lung adenocarcinoma cells in vivo. To investigate whether the gefitinib sensitivity of lung cancer cells with EGFR-activating mutations could be affected by fibroblasts in vivo, we inoculated PC-9 cells, with or without MRC-5 cells, into SCID mice subcutaneously. The tumors in mice injected with PC-9 plus MRC-5 cells grew slightly faster than the tumors in mice injected with PC-9 cells alone. Gefitinib treatment, beginning on day 4, caused marked regression of tumors in mice injected with PC-9 cells alone. The same treatment prevented enlargement of tumors in mice injected with PC-9 and MRC-5 cells, but it did not cause tumor regression, indicating resistance of the tumors to gefitinib treatment in vivo (Fig. 6A).

To further elucidate the role of HGF in vivo, the mice bearing tumors caused by injection of PC-9 and MRC-5 cells were treated with anti-HGF neutralizing antibody or NK4 in the presence or absence of gefitinib. Treatment with anti-HGF antibody or NK4 alone marginally reduced the tumor growth. Treatment with gefitinib alone prevented tumor enlargement, but it did not cause significant regression of tumor size. Importantly, the combination of gefitinib with anti-HGF antibody or NK4 caused marked tumor regression (Fig. 6B). These results indicate that HGF, produced presumably by fibroblasts (MRC-5), induced in vivo gefitinib resistance in lung cancer cells with EGFR-activating mutations.

In the final set of experiments, we confirmed HGF production by MRC-5 cells in vivo. Whereas the tumors in mice injected with PC-9 cells alone did not produce detectable levels of HGF, the tumors in mice injected with PC-9 and MRC-5 cells produced high levels of HGF on day 4, which decreased on day 7 (Fig. 6C). The decrease of HGF levels in the tumors may be the reason for incomplete resistance to gefitinib induced by the coinjected MRC-5 cells. On the other hand, we could not detect human HGF in the serum of mice implanted with PC-9 and MRC-5 cells (data not shown), suggesting that HGF level in the tumor area may be more important to predict the resistance to EGFR-TKIs. To confirm the presence of MRC-5 cells in the tumor, red fluorescence–labeled MRC-5 cells were mixed with PC-9 cells before inoculation and shown to be present in these tumors (Supplementary Fig. S2A). Compared with PC-9 alone tumors, more infiltrating fibroblast-like cells were found in the coinjected tumors (Supplementary Fig. S2B). Moreover, double staining for type I collagen and human HGF clearly showed that the infiltrating fibroblasts produced HGF (Fig. 6D). These results indicate that the human fibroblast cell line MRC-5, when inoculated along with PC-9 cells, produced HGF and hence induced gefitinib resistance as tumor-associated fibroblasts.

**Discussion**

We have shown here that a novel crosstalk between tumor and stromal fibroblasts is responsible for inducing resistance to TKIs in lung cancers harboring EGFR-activating mutations. Cancer cells recruit fibroblasts, which produce HGF that induces EGFR-TKI resistance in lung cancer cells harboring EGFR-activating mutations by activating the MET/P13K/Akt axis. We further showed that EGFR-TKI resistance induced by fibroblast-derived HGF could be circumvented by HGF-MET inhibitors in both in vitro and in vivo experimental models. These results indicate that a novel strategy, targeting the crosstalk between tumor cells and stromal fibroblasts, may be important for circumventing the EGFR-TKI resistance of lung cancers harboring EGFR-activating mutations.

The tumor microenvironment is important for tumor progression. Fibroblastic stromal cells have been linked to several activities that promote tumor progression, including angiogenesis,
epithelial-to-mesenchymal transition, progressive genetic instability, deregulation of antitumor immune responses, enhanced metastasis, and enhanced growth. Stromal fibroblasts act as a major source of chemoattractants, which facilitate tumor cell motility and metastasis. In a contrasting situation, fibroblasts frequently infiltrate into tumors, but the mechanism underlying this infiltration is still poorly understood (27, 28).

We found that the lung cancer cell lines, PC-9 and HCC827, induced recruitment of fibroblasts but that this recruitment was not significantly affected by inhibition of fibronectin, fibroblast growth factor-2/fibroblast growth factor receptor-1, platelet-derived growth factors/platelet-derived growth factor receptors, stromal cell-derived factor-1, interleukin-8, or stromal cell-derived factor-1 plus interleukin-8 (data not shown). Interestingly, this recruitment was further enhanced by addition of gefitinib to the culture. Taken together, these findings indicate that PC-9 and HCC827 cells damaged by gefitinib treatment released unknown chemoattractants, which led to enhanced fibroblast recruitment. Thus, dying lung cancer cells likely release chemoattractants to recruit fibroblasts that secrete HGF, thus protecting live lung cancer cells from gefitinib. Further examinations are ongoing in our laboratory to identify the chemotactic factor(s) responsible for this phenomenon.

We reported previously that HGF, either exogenously added or overexpressed in lung cancer cells harboring EGFR-activating mutations, caused gefitinib resistance by restoring the MET/PI3K/Akt axis (11). In the present study, we confirmed these findings and further extended these observations, showing that gefitinib resistance could also be induced by HGF derived from both fibroblast cell lines and primary cultured fibroblasts by a paracrine mechanism. Fibroblast cell lines have been found to produce higher concentrations of HGF than other cell types,

Fig. 6. Fibroblast-derived HGF induces gefitinib resistance in PC-9 tumors in SCID mice. PC-9 cells (5 x 10^6) with or without MRC-5 cells (5 x 10^6) were inoculated subcutaneously into SCID mice on day 0. Mice received oral gefitinib (25 mg/kg/d) or vehicle only, starting on day 4. A, coinjection with MRC-5 cells induces resistance of PC-9 tumors to gefitinib treatment. The tumor area was measured every 3 or 4 d and calculated as described in Materials and Methods. Bar, SE. B, anti-HGF antibody or NK4 reverses gefitinib resistance in tumors caused by injection of PC-9 cells mixed with MRC-5 cells. Mice received oral gefitinib (25 mg/kg/d), with or without anti-HGF neutralizing antibody (5 mg/kg/d) or NK4 (9 mg/kg/d) intraperitoneally daily, starting on day 4. Bar, SE. C, HGF production in tumor tissues. The tumors were harvested on day 4 or 7 and lysed. HGF production in tumor tissue lysate was examined by ELISA. D, colocalization of MRC-5 cells and HGF in tumors caused by injection of PC-9 and MRC-5 cells. Tumors were harvested on day 14. Frozen tumor specimens were subjected to triple-color immunofluorescence analyses using the combination of anti-type I collagen antibody (green), anti-HGF antibody (red), and 4',6-diamidino-2-phenylindole (blue) as described in Materials and Methods. The fluorescent images were digitally merged. Original magnification, ×200.
including endothelial cells and lung cancer cell lines (11, 29). Moreover, primary cultured fibroblasts established from tu-
mors of lung cancer patients produced various levels of HGF in vitro. Therefore, it is highly possible that tumor-associated fib-
roblasts are involved in both intrinsic and acquired resistance to gefitinib and erlotinib observed in lung cancer patients harboring
EGFR-activating mutations.

Several prospective studies indicate that, although lung can-
cer patients harboring EGFR-activating mutations (superrespon-
ders) show dramatic responses to gefitinib or erlotinib, the rate of complete response (radiographic disappearance of tumors) is very low (3–6). Many superresponders retain a small tumor remnant, which is maintained for months to years. Two me-
chanisms, T790M second mutation in EGFR (8) and MET ampli-
fication (9), have been reported associated with acquired resistance to gefitinib or erlotinib in lung cancer patients with EGFR-activating mutations. Continuous treatment with gefitinib or erlotinib may select minor clones with a T790M second mutation and/or MET amplification. Alternatively, cancer cells may acquire these alterations during continuous treatment with gefitinib or erlotinib. However, if the majority of cancer cells in the small tumor remnant have T790M second mutation and/or MET amplification, the tumor remnant will enlarge in a short period. Therefore, it would seem difficult for these two mechan-
isms to explain why the size of the tumor remnant is main-
tained for months to years during treatment with gefitinib or erlotinib. We found that fibroblast-derived HGF contributed to the persistence of tumors during gefitinib treatment. These findings suggest that fibroblasts recruited to tumors may protect tumors by producing HGF until minor clones with T790M and/or MET amplification become dominant. Further studies are required to assess this hypothesis.

The results of our previous (11) and present studies showed that HGF derived from cancer cells or stromal fibroblasts in-
duces gefitinib resistance in lung cancers harboring EGFR-
activating mutations. Therefore, HGF-MET may be an ideal target for circumventing this type of resistance. We found that several HGF-MET inhibitors, including anti-HGF antibody, the natural inhibitor NK4, and MET-TKI (14, 30–34), could abrogate HGF-
induced gefitinib resistance, with anti-HGF neutralizing anti-
body and NK4 completely abrogating HGF-induced resistance to gefitinib in vitro and in vivo. In contrast, a nontoxic concent-
ation of the MET-TKI, SU11274, had a smaller effect than ei-
ther anti-HGF antibody or NK4. Newer MET-TKIs, with higher activity, are currently being evaluated in clinical trials against various cancers, including gastric cancers and renal cell carci-
nomas with MET mutations or amplification (35, 36). Therefore, these new MET-TKIs may be more effective in lung cancer pa-
patients with EGFR-TKI resistance. Additional studies are re-
quired to determine the relative efficacy and safety of agents in treating lung cancer patients with HGF-induced gefitinib resistance.

In summary, we showed that a novel crosstalk between tu-
mor cells and stromal fibroblasts is responsible for the resis-
tance to EGFR-TKIs of lung cancers harboring EGFR-activating
mutations. These results suggest that new strategies targeting this crosstalk may be important for circumventing resistance to EGFR-TKIs of lung cancers harboring EGFR-activating
mutations.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Schiller JH, Harrington D, Belani CP, et al. East-
2. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemci-
tabine, and cisplatin plus vinorelbine for ad-
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor recep-
4. Paez JG, Janne PA, Lee JC, et al. EGFR muta-
tions in lung cancer: correlation with clinical re-
sponse to gefitinib therapy. Science 2004;304:
1497–500.
5. Mitsudomi T, Yatabe Y. Mutations of the epider-
mal growth factor receptor gene and related genes as determinants of epidermal growth factor recep-
6. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-
naive patients with advanced non-small-cell lung cancer with epidermal growth factor recep-
tor gene mutations. J Clin Oncol 2006;24:
3340–6.
786–92.
8. Pao W, Miller VA, Politi KA, et al. Acquired re-
sistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second muta-
cence 2007;316:1039–43.
10. Bean J, Brennan C, Shih JY, et al. MET ampli-
fication occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl
growth factor induces gefitinib resistance of lung adeno-
carcinoma with epidermal growth factor recep-
tor-activating mutations. Cancer Res 2008;68:
9479–87.
elocular cloning and expression of human hep-
17. Bissell MJ, Radisky D. Putting tumours in con-
18. Ogino A, Kitao H, Hirano S, et al. Emergence of epidermal growth factor receptor T790M muta-
20. Tomioka D, Maehara N, Kuba K, et al. Inhibi-
tion of growth, invasion, and metastasis of hu-
man pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 2001;61:
7518–24.
pression of hepatocyte growth factor and c-Met in the anterior horn cells of the spinal cord in the patients with amyotrophic lateral sclerosis
(ALS): immunohistochemical studies on sporad-
ic ALS and familial ALS with superoxide dismu-
22. Barker SE, Grosse SM, Siapati EK, et al. Immu-
notherapy for neuroblastoma using syngeneic fi-
broblasts transfected with IL-2 and IL-12. Br J
23. Green LM, Reade JL, Ware CF. Rapid colorimetric assay for cell viability: application to the quantita-


Clinical Cancer Research

Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Wei Wang, Qi Li, Tadaaki Yamada, et al.

Clin Cancer Res  Published OnlineFirst October 20, 2009.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-09-1001

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2009/10/16/1078-0432.CCR-09-1001.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.